MX2023013149A - Anticuerpos anti-il-27 y usos de estos. - Google Patents

Anticuerpos anti-il-27 y usos de estos.

Info

Publication number
MX2023013149A
MX2023013149A MX2023013149A MX2023013149A MX2023013149A MX 2023013149 A MX2023013149 A MX 2023013149A MX 2023013149 A MX2023013149 A MX 2023013149A MX 2023013149 A MX2023013149 A MX 2023013149A MX 2023013149 A MX2023013149 A MX 2023013149A
Authority
MX
Mexico
Prior art keywords
antibodies
antigen
relates
ameliorating
symptoms
Prior art date
Application number
MX2023013149A
Other languages
English (en)
Inventor
Benjamin Lee
Robert Ross
Kerry White
Alison O''neill
Lauren Harshman
Jonathan Hill
Jou- Ku CHUNG
Original Assignee
Surface Oncology Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surface Oncology Llc filed Critical Surface Oncology Llc
Publication of MX2023013149A publication Critical patent/MX2023013149A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se relaciona con anticuerpos anti-IL-27, y porciones de unión a antígeno de estos. La divulgación también se relaciona con métodos para tratar o mejorar uno o más síntomas de una enfermedad, como el cáncer, administrando los anticuerpos o la porción de unión a antígeno de estos a una dosis de al menos aproximadamente 0.003 mg/kg a al menos aproximadamente 20 mg/kg.
MX2023013149A 2021-05-07 2022-05-06 Anticuerpos anti-il-27 y usos de estos. MX2023013149A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163185989P 2021-05-07 2021-05-07
US202163203688P 2021-07-28 2021-07-28
US202163277035P 2021-11-08 2021-11-08
PCT/US2022/028189 WO2022236134A1 (en) 2021-05-07 2022-05-06 Anti-il-27 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
MX2023013149A true MX2023013149A (es) 2023-11-28

Family

ID=81928149

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013149A MX2023013149A (es) 2021-05-07 2022-05-06 Anticuerpos anti-il-27 y usos de estos.

Country Status (10)

Country Link
US (1) US20220389089A1 (es)
EP (1) EP4334348A1 (es)
JP (1) JP2024516970A (es)
KR (1) KR20240005809A (es)
AU (1) AU2022270170A1 (es)
CA (1) CA3215856A1 (es)
IL (1) IL308198A (es)
MX (1) MX2023013149A (es)
TW (1) TW202304981A (es)
WO (1) WO2022236134A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024110405A1 (en) * 2022-11-22 2024-05-30 Institut National de la Santé et de la Recherche Médicale Use of il-27 antagonists for the treatment of ebv-driven b lymphoproliferative diseases

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
JPH08511420A (ja) 1993-06-16 1996-12-03 セルテック・セラピューテイクス・リミテッド 抗 体
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
WO1995020401A1 (en) 1994-01-31 1995-08-03 Trustees Of Boston University Polyclonal antibody libraries
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6001329A (en) 1996-05-06 1999-12-14 Uab Research Foundation Radiolabeled fusion toxins for cancer therapy
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6995259B1 (en) 1998-10-23 2006-02-07 Sirna Therapeutics, Inc. Method for the chemical synthesis of oligonucleotides
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
CA2824805A1 (en) * 2011-01-14 2012-07-19 Five Prime Therapeutics, Inc. Il-27 antagonists for treating inflammatory diseases
KR101981873B1 (ko) 2011-11-28 2019-05-23 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN104470949A (zh) 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
US10239942B2 (en) 2014-12-22 2019-03-26 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
PE20200717A1 (es) 2017-06-22 2020-07-21 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas
KR20230020023A (ko) 2018-03-14 2023-02-09 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
WO2021062244A1 (en) * 2019-09-25 2021-04-01 Surface Oncology, Inc. Anti-il-27 antibodies and uses thereof

Also Published As

Publication number Publication date
TW202304981A (zh) 2023-02-01
CA3215856A1 (en) 2022-11-10
US20220389089A1 (en) 2022-12-08
WO2022236134A1 (en) 2022-11-10
KR20240005809A (ko) 2024-01-12
IL308198A (en) 2024-01-01
AU2022270170A1 (en) 2023-09-21
JP2024516970A (ja) 2024-04-18
EP4334348A1 (en) 2024-03-13

Similar Documents

Publication Publication Date Title
CR20220363A (es) Compuestos tricíclicos sustituidos
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
WO2007145941A3 (en) Administration of anti-cd3 antibodies in the treatment of autoimmune diseases
MX2022007276A (es) Tratamiento de la esclerosis amiotrofica lateral y enfermedades relacionadas.
IN2012DN02826A (es)
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
WO2021239935A9 (en) Neutralizing antibodies against sars-related coronavirus
MX2021012769A (es) Anticuerpos bloqueadores cd73.
MX2023013149A (es) Anticuerpos anti-il-27 y usos de estos.
MX2022005903A (es) Métodos para tratar el cáncer de mama her2 positivo con tucatinib en combinación con un conjugado fármaco-anticuerpo anti-her2.
MX2022004678A (es) Anticuerpo anti-beta amiloide para el tratamiento de la enfermedad de alzheimer.
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
MX2022001084A (es) Metodo de tratamiento de la enfermedad de alzheimer mediante la regulacion de microrganismos intestinales.
MX2022003719A (es) Anticuerpos anti-il-27 y sus usos.
MX2023006578A (es) Heteroaril-acetilenos, sus composiciones farmacéuticas y sus aplicaciones terapéuticas.
MX2021006242A (es) Formulaciones de capsula.
MX2021008081A (es) Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa.
MX2022003845A (es) Tratamientos cognitivos medicinales.
BR112021022503A2 (pt) Métodos de administração de anticorpo anti-cd38 para tratar mieloma múltiplo
WO2023278897A9 (en) Compositions and methods for treating cancers
BR112014014805A2 (pt) processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
MX2023000763A (es) Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
MX2022010513A (es) Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton.